Antigenic Targets in Clear Cell Renal Cell Carcinoma

Overview

Journal Kidney Cancer

Date 2023 Nov 28

PMID 38014393

Authors

Nicholas R Schindler

David A Braun

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitors (ICIs) have transformed the management of advanced renal cell carcinoma (RCC), but most patients still do not receive a long-term benefit from these therapies, and many experience off-target, immune-related adverse effects. RCC is also different from many other ICI-responsive tumors, as it has only a modest mutation burden, and total neoantigen load does not correlate with ICI response. In order to improve the efficacy and safety of immunotherapies for RCC, it is therefore critical to identify the antigens that are targeted in effective anti-tumor immunity. In this review, we describe the potential classes of target antigens, and provide examples of previous and ongoing efforts to investigate and target antigens in RCC, with a focus on clear cell histology. Ultimately, we believe that a concerted antigen discovery effort in RCC will enable an improved understanding of response and resistance to current therapies, and lay a foundation for the future development of "precision" antigen-directed immunotherapies.

References

Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C . Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012; 18(8):1254-61. DOI: 10.1038/nm.2883. View

Demasure S, Spriet I, Debruyne P, Laenen A, Wynendaele W, Baldewijns M . Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. Acta Oncol. 2021; 61(1):22-29. DOI: 10.1080/0284186X.2021.1989720. View

Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R . The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol. 2011; 5(2):164-82. PMC: 5528287. DOI: 10.1016/j.molonc.2011.02.001. View

Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading J . Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017; 18(8):1009-1021. DOI: 10.1016/S1470-2045(17)30516-8. View

Jansen C, Prokhnevska N, Master V, Sanda M, Carlisle J, Bilen M . An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature. 2019; 576(7787):465-470. PMC: 7108171. DOI: 10.1038/s41586-019-1836-5. View

Gaugler B, Brouwenstijn N, Vantomme V, Szikora J, Van der Spek C, Patard J . A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics. 1996; 44(5):323-30. DOI: 10.1007/BF02602776. View

Hansen U, Ramskov S, Bjerregaard A, Borch A, Andersen R, Draghi A . Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations. Front Immunol. 2020; 11:373. PMC: 7080703. DOI: 10.3389/fimmu.2020.00373. View

Berinstein N, Karkada M, Oza A, Odunsi K, Villella J, Nemunaitis J . Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncoimmunology. 2015; 4(8):e1026529. PMC: 4570133. DOI: 10.1080/2162402X.2015.1026529. View

Sahin U, Oehm P, Derhovanessian E, Jabulowsky R, Vormehr M, Gold M . An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020; 585(7823):107-112. DOI: 10.1038/s41586-020-2537-9. View

10.

Kaufman H, Taback B, Sherman W, Kim D, Shingler W, Moroziewicz D . Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med. 2009; 7:2. PMC: 2631474. DOI: 10.1186/1479-5876-7-2. View

11.

Stern P, Harrop R . 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer. Cancer Immunol Immunother. 2016; 66(4):415-426. PMC: 11029567. DOI: 10.1007/s00262-016-1917-3. View

12.

Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon P, Kandalaft L . Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results. Front Immunol. 2019; 10:766. PMC: 6470191. DOI: 10.3389/fimmu.2019.00766. View

13.

Chamie K, Donin N, Klopfer P, Bevan P, Fall B, Wilhelm O . Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. JAMA Oncol. 2016; 3(7):913-920. PMC: 5824229. DOI: 10.1001/jamaoncol.2016.4419. View

14.

Ng K, Boumelha J, Enfield K, Almagro J, Cha H, Pich O . Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature. 2023; 616(7957):563-573. PMC: 10115647. DOI: 10.1038/s41586-023-05771-9. View

15.

Lin L, Zhong K, Sun Z, Wu G, Ding G . Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma. J Cancer Res Clin Oncol. 2011; 138(1):11-22. DOI: 10.1007/s00432-011-1067-0. View

16.

Atkins M, Lotze M, Dutcher J, Fisher R, Weiss G, Margolin K . High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999; 17(7):2105-16. DOI: 10.1200/JCO.1999.17.7.2105. View

17.

Choueiri T, Powles T, Burotto M, Escudier B, Bourlon M, Zurawski B . Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021; 384(9):829-841. PMC: 8436591. DOI: 10.1056/NEJMoa2026982. View

18.

Kassiotis G, Stoye J . Immune responses to endogenous retroelements: taking the bad with the good. Nat Rev Immunol. 2016; 16(4):207-19. DOI: 10.1038/nri.2016.27. View

19.

Carreno B, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti A . Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015; 348(6236):803-8. PMC: 4549796. DOI: 10.1126/science.aaa3828. View

20.

Motzer R, Alekseev B, Rha S, Porta C, Eto M, Powles T . Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021; 384(14):1289-1300. DOI: 10.1056/NEJMoa2035716. View